Product Pipeline

Our cutting edge anti-bacteria and anti-fungal products are quickly progressing through target identification, lead selection and optimization, and nonclinical testing phases.

Our anti-inflammatory product with our co-development partner achieved US NDA approval in March 2024.

All of our anti-infective programs are funded by the National Institutes of Health via the SBIR grants. It is of utmost importance to AimMax Therapeutics to protect the objectivity and integrity of its research and development activities to ensure public trust and to meet scientific and ethical standards of the NIH-funded research. To view AimMax Therapeutics Financial Conflict of Interest (FCOI) Policy, please click here.

Product Pipeline: Text